Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108862 · ClinicalTrials.gov registry record · Phase 4
Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis
A Phase 4 study, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Completed
- Registry status
- Phase 4
- Development phase
- 809
- Enrollment target
NCT00108862 is a Phase 4 study that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 809 participants.
The verdict
NCT00108862, a Phase 4 study, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 809 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the best time to begin anti-HIV treatment in individuals who have HIV and tuberculosis (TB). Study hypothesis: Immediate antiretroviral therapy (ART), initiated after approximately 2 weeks of TB treatment, will reduce the frequency of other AIDS-defining illnesses and death in HIV-infected participants being treated for TB by at least 40% at week 48 when compared to deferred ART, initiated at after 8-12 weeks of TB treatment.
Interventions
- OTHER Strategy: Immediate ART
- OTHER Strategy: Deferred ART
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 809 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108862
The ClinicalTrials.gov registry entry for NCT00108862 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 809 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Strategy: Immediate ART is the first listed.
NCT00108862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108862 about?
NCT00108862 is a clinical study titled "Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis". The purpose of this study is to determine the best time to begin anti-HIV treatment in individuals who have HIV and tuberculosis (TB). Study hypothesis: Immediate antiretroviral therapy (ART), initiated after approximately 2 weeks of TB treatment, will reduce the frequency of other AIDS-defining il...
What is the current status of trial NCT00108862?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 809 participants. The study started on 2006-08. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00108862?
The interventions under investigation include: Strategy: Immediate ART (OTHER), Strategy: Deferred ART (OTHER).
Who is sponsoring clinical trial NCT00108862?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.